Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | DNM1 | Q05193 | 5/20 | 0.37 |
| ▸ | FAAH | O00519 | 2/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17336085 | 1.00 | TSHR (0.41) | TSHRSMN1; SMN2DNM1FAAHTRPV1 | |
| SCHEMBL10490298 | 1.00 | TSHR (0.41) | TSHRSMN1; SMN2DNM1FAAHTRPV1 | |
| SCHEMBL17336097 | 1.00 | TSHR (0.41) | TSHRSMN1; SMN2DNM1FAAHTRPV1 | |
| SCHEMBL11246678 | 1.00 | TSHR (0.41) | TSHRSMN1; SMN2DNM1FAAHTRPV1 | |
| SCHEMBL1978740 | 0.91 | TSHR (0.52) | TSHRSMN1; SMN2DNM1FAAHTRPV1 | |
| SCHEMBL418279 | 0.91 | TSHR (0.46) | TSHRSMN1; SMN2DNM1FAAHTRPV1 | |
| SCHEMBL6892024 | 0.91 | TSHR (0.52) | TSHRSMN1; SMN2DNM1FAAHTRPV1 | |
| SCHEMBL1812024 | 0.91 | TSHR (0.52) | TSHRSMN1; SMN2DNM1FAAHTRPV1 | |
| SCHEMBL10529071 | 0.91 | TSHR (0.46) | TSHRSMN1; SMN2DNM1FAAHTRPV1 | |
| SCHEMBL4053772 | 0.91 | TSHR (0.52) | TSHRSMN1; SMN2DNM1FAAHTRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3068913-B1 | METHOD FOR SEPARATING NICKEL AND COBALT FROM NICKEL LATERITES AND NICKEL LATERITE LEACH SOLUTIONS | OUTOTEC FINLAND OY (FI) | 2019-01-02 | — | — | EP | disclosed |
| CN-101467276-A | Liquid crystalline rylene tetracarboxylic acid derivatives and use thereof | MAX PLANCK GESELLSCHAFT (DE) | 2009-06-24 | — | — | CN | disclosed |
| US-20030073668-A1 | Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors | BOOTH RICHARD JOHN (US) | 2003-04-17 | — | — | US | disclosed |
| US-4193969-A | USING A-HYDROXYOXIMES AND SULFONIC ACIDS | AMAX INC. (US) | 1980-03-18 | — | — | US | disclosed |
| US-4104359-A | TREATING WITH SALT OF HYDROXYLAMINE | AMAX INC. (US) | 1978-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073668-A1 | Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors | CDK9, CDK19, CDK3 | TSHR 351/4885SMN1; SMN2 3957/4885DNM1 4000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.